A Pospective, Single-arm, Multicenter Clinical Trial Evaluating Preoperative Neoadjuvant mFOLFOX6 Chemotherapy in Combination With PD1 Monoclonal Antibody in MSS/pMMR Locally Advanced Rectal Cancer

NCT06688786 · tracked via the Priya Life Science China tracker

Sponsor

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Phase

Not applicable

Started

2024-11-01

Last updated

2026-01-27

Condition(s) studied

Locally Advanced Rectal Cancer (LARC)

Investigational drug(s) / intervention(s)

neoadjuvant mFOLFOX6 chemotherapy combined with PD-1 inhibitor therapy

neoadjuvant mFOLFOX6 chemotherapy combined with PD-1 inhibitor therapy: Preoperative treatment with 4-6 cycles of mFOLFOX6 regimen combined with serplulimab

Study summary

Preoperative neoadjuvant chemoradiotherapy can induce tumor regression and reduce the risk of postoperative recurrence, serving as the standard treatment for locally advanced rectal cancer. However, neoadjuvant radiotherapy may increase the risk of postoperative complications, proctitis, enteritis, and reduced anal function. Exploring radiation-free approaches to prevent the effects of radiotherapy toxicity on postoperative complications and quality of life is now a significant research focus. Neoadjuvant chemotherapy represents a promising approach in the neoadjuvant treatment of rectal cancer. Neoadjuvant chemotherapy avoids the impact of radiotherapy on organ function, reduces the incidence of postoperative anastomotic leakage, and is beneficial for long-term anal function preservation. However, its low tumor regression rate limits its application in the neoadjuvant treatment of rectal cancer. For patients with locally advanced rectal cancer, there is an urgent need for a new neoadjuvant treatment strategy that can both significantly improve tumor regression rates and reduce the risk of postoperative anastomotic leakage, and protect long-term anal function. PD-1 inhibitors are highly effective in treating microsatellite instability-high (MSI-H) colorectal cancer patients, but show poor efficacy in the 95% of patients with microsatellite stable (MSS) tumors. The challenge now is to find combination therapies that can convert tumors into an "immune-activated tumor," thereby enhancing the effectiveness of immunotherapy in MSS patients. Oxaliplatin and 5-fluorouracil have roles in releasing tumor antigen epitopes, activating CD8+ cells, and reshaping the immune microenvironment. Multiple clinical studies and animal experiments have shown that combining PD-1 antibodies with FOLFOX generates a synergistic effect, showing strong antitumor activity. This study evaluates the efficacy, safety, and impact on postoperative anal function of preoperative neoadjuvant treatment with FOLFOX chemotherapy combined with PD-1 inhibitors in patients with MSS-type advanced rectal cancer. The radiotherapy-free approach aims to avoid radiotherapy-related toxicity, offering significant potential to enhance the efficacy of neoadjuvant chemotherapy, improve long-term survival, and protect anal function.

Eligibility

Sex

ALL

Min age

18 Years

Max age

75 Years

Healthy volunteers

Inclusion Criteria: 1. Advanced (cT3-4NxM0 or cTxN+M0) rectal cancer with the lower tumor margin within 15 cm of the anal verge 2. Histopathology confirmed adenocarcinoma with an pMMR/MSS genetic profile. 3. Absence of bowel obstruction, or bowel obstruction relieved by proximal colostomy. 4. Age: 18-75 5. ECOG: 0-1 6. No prior chemotherapy, radiotherapy, targeted therapy, or immunotherapy received. 7. Female participants must be non-lactating, with a negative pregnancy test result. Exclusion Criteria: 1. Patients with distant metastasis 2. History of receiving chemotherapy, radiotherapy, targeted therapy, or immunotherapy. 3. Active autoimmune disease requiring systemic treatment within the 2 years prior to enrollment. 4. History of other malignancies within the past 5 years, excluding cured cervical carcinoma in situ or basal cell carcinoma of the skin. 5. History of HIV infection, or active chronic hepatitis B or C with high viral DNA copy numbers. 6. Patients with active tuberculosis currently receiving anti-tuberculosis treatment or treated with anti-tuberculosis therapy within the past year prior to screening. 7. Known or suspected allergy to the study drug or any study-related medications administered. 8. Presence of severe cardiovascular or cerebrovascular disease. 9. Within 14 days prior to the first dose, presence of a severe active or uncontrolled infection requiring systemic therapy, or unexplained fever \>38.5°C. 10. Receiving systemic corticosteroid treatment or other immunosuppressive agents within 14 days prior to the first dose, or immunostimulants within 4 weeks. 11. History of confirmed neurological or psychiatric disorders, including epilepsy or dementia. 12. The participant may be unable to complete the study due to other reasons, or the investigator considers them unsuitable for inclusion. 13. Refusal to sign the informed consent form.

Primary outcome measure(s)

Pathological complete response — Day 7 after surgery
Major Pathological Response — Day 7 after surgery

Trial sites (1)

Facility	City	Region	Status
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine	Shanghai	Shanghai Municipality

More Xinhua Hospital, Shanghai Jiao Tong University School of Medicine trials in China

A Study on the Correlation Between Oral Health and Delirium in Surgical Inpatients Recruiting

Preconception vs First-Trimester Screening and Treatment for Iron Deficiency Anemia Recruiting

Predicting Risk Factors for Exacerbation of Chronic Obstructive Pulmonary Disease Recruiting

Genotype-Phenotype Correlations in Patients With Alport Syndrome Recruiting

Predicting the Metabolic Biomarkers Associated With Injury in Athletes Enrolling by invitation

Other trials for the same condition

Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer Recruiting

To Explore a Single-arm Phase II Study on Intestinal Microbiota Transplantation Combined With Neoadjuvant Immunotherapy and Chemoradiotherapy for Locally Advanced Rectal Cancer Under MSS/pMMR Starting soon

PCSK9 Inhibitor and PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy for pMMR/MSS Locally Advanced Rectal Cancer Active, not recruiting

Short-Course Online Adaptive Radiotherapy Combined With Chemotherapy, Targeted Therapy and Immunotherapy as Total Neoadjuvant Therapy (TNT) for Locally Advanced Rectal Cancer Starting soon

SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Cancer Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06688786 on ClinicalTrials.gov ↗ ← All trials in China